Systemic effects of cystic fibrosis transmembrane conductance regulator modulators on the plasma and serum proteome (opens in new tab)

CFTR modulator drugs improve the function of mutant CFTR and significantly improve clinical outcomes in people with cystic fibrosis (pwCF). This study identifies specific and common signatures associated with inflammation and metabolic processes in the plasma and serum proteomes of pwCF treated with the CFTR modulator combinations lumacaftor/ivacaftor or elexacaftor/tezacaftor/ivacaftor.